Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · IEX Real-Time Price · USD
57.69
+0.15 (0.26%)
At close: Jul 26, 2024, 4:00 PM
56.53
-1.16 (-2.01%)
After-hours: Jul 26, 2024, 6:29 PM EDT
PRAX Revenue
Praxis Precision Medicines had revenue of $431.00K in the quarter ending March 31, 2024, a decrease of -36.90%. This brings the company's revenue in the last twelve months to $2.20M, up 221.38% year-over-year. In the year 2023, Praxis Precision Medicines had annual revenue of $2.45M.
Revenue (ttm)
$2.20M
Revenue Growth
+221.38%
P/S Ratio
449.64
Revenue / Employee
$26,768
Employees
82
Market Cap
986.95M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Embecta | 1.13B |
OPKO Health | 799.60M |
Pacira BioSciences | 681.75M |
CareDx | 275.11M |
Bicycle Therapeutics | 41.61M |
Silence Therapeutics | 33.86M |
ARS Pharmaceuticals | 10.00K |
PRAX News
- 7 weeks ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024 - GlobeNewsWire
- 3 months ago - Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting - GlobeNewsWire
- 4 months ago - Praxis Precision Medicines to Participate in Upcoming April Conferences - GlobeNewsWire
- 4 months ago - Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering - GlobeNewsWire
- 4 months ago - Praxis Precision Medicines, Inc. Announces Proposed Public Offering - GlobeNewsWire